SAN FRANCISCO, CA – (October 29, 2025) – National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Baxter International, Inc. (“Baxter”) (NYSE: BAX) who purchased or otherwise acquired Baxter common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”) to contact us immediately regarding the pending securities class action against Fiserv. The deadline to apply to be lead plaintiff is December 15, 2025.
Class Period: February 23, 2022 – July 30, 2025
Lead Plaintiff Motion Deadline: December 15, 2025
Case information: https://lieffcabraser.com/securities/baxter/
Contact us: Email or text investorinfo@lchb.com or call 1-800-541-7358
Baxter, headquartered in Deerfield, Illinois, develops, manufactures, and markets medical products used in the healthcare industry. The Company recently launched the Novum LVP, a device that controls the delivery of intravenous (“IV”) fluids that carry medications, blood products, and nutrients to patients.
The action alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (a) Novum LVPs had been hampered by systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which subject patients to serious risk of injury or death; (b) Baxter was notified of those Novum LVP malfunctions and related injuries and deaths; (c) Baxter’s attempts to remedy those defects were inadequate and Novum LVP’s design flaws continued to cause serious harm to patients; and (d) as a result of the foregoing, there was a significant risk that Novum LVP customers would be asked to discontinue using existing Novum LVPs and that Baxter would pause new sales of the devices.
On April 7, 2025, Missouri news outlet KMOV reported significant safety issues with Novum LVP, specifically regarding the device’s inaccurate infusion rates, based on information from a whistleblower. The KMOV report prompted the hospital system to take all its Novum LVPs out of service. Baxter nevertheless continued to promote the launch of Novum LVP and claimed it was a safe product.
On April 24, 2025, Baxter sent Novum LVP customers a warning letter about the device’s potential underinfusion risks and disclosed there had been only one serious injury linked to this issue.
On July 14, 2025, Baxter sent Novum LVP customers a second warning letter about the device’s risk of both underinfusion and overinfusion. The letter also disclosed that Baxter had received 79 serious injury reports and two reports of patient deaths tied to the device’s safety issues. Baxter, however, did not instruct hospitals to remove their Novum LVPs from service but rather directed them on correction steps while continuing to use the devices.
On July 31, 2025, Baxter announced that it was “voluntarily and temporarily paus[ing] shipments and planned installations of the Novum LVP,” and that the Company was “unable to currently commit to an exact timing for resuming shipment[s] and installation[s] for Novum LVPs.” Baxter’s Chief Operating Officer explained that the sales halt was in response to issues “we saw through our quality listening systems, customer feedback, and honestly our infusion data.” Following this news, Baxter’s stock price fell $6.29 per share, or 22.42%, from its closing price of $28.05 on July 30, 2025, to close at $21.76 on July 31, 2025, on significantly elevated trading volume.
About Lieff Cabraser
Lieff Cabraser Heimann & Bernstein, LLP, with over 125 attorneys in offices in San Francisco, New York, Nashville, and Munich, Germany, is an internationally-recognized law firm committed to advancing the rights of investors and promoting corporate responsibility. Repeatedly recognized as a “Plaintiffs’ Powerhouse” by Law360, Lieff Cabraser has litigated some of the most important civil cases in the United States, and has assisted clients in recovering over $129 billion in verdicts and settlements. For over 50 years, Lieff Cabraser has remained committed to ensuring access to justice for all.
Source/Contact
Sharon Lee
Lieff Cabraser Heimann & Bernstein, LLP
415 956-1000
slee@lchb.com
Contact us
Use the form below to contact a lawyer at Lieff Cabraser.
